This study examined if long-term dulaglutide (Trulicity) treatment could reduce kidney disease symptoms in patients with Type 2 diabetes (T2D). The authors concluded that dulaglutide improved some symptoms of kidney disease over five years compared to placebo.

This study examined the factors that predict changes in weight in rheumatoid arthritis patients.

This study looked at patient-reported side effects associated with methotrexate (Rheumatrex) when taken in tablet form or by injection for rheumatoid arthritis (RA). The authors concluded that there are a number of side effects associated with both forms of methotrexate that may not be recorded during routine treatment.

This study evaluated whether the ‘suspend-before-low’ feature of automatic insulin pumps prevented hypoglycemia (HG) in patients with Type 1 diabetes (T1D). The authors concluded that this feature successfully reduced the rate of HG and was not associated with increased side effects.

This study analyzed the safety of disease-modifying anti-rheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA).

They found that patients taking biological DMARDs had a higher risk of infections compared to synthetic DMARDs.

This study compared IDegLira (Xultophy) to insulin degludec (Tresiba) or liraglutide (Victoza) alone in patients with uncontrolled Type 2 diabetes (T2D). The authors concluded that combined IDegLira was more effective and had fewer side effects than either insulin medication alone.

This study looked at the long term effect on health-related quality of life in adults who were diagnosed with juvenile idiopathic arthritis as children. The authors concluded that health-related quality of life was reduced in adults who had juvenile idiopathic arthritis as children. 

This study evaluated the effects of low blood pressure when standing up (orthostatic hypotension; OH) on cognitive (mental) function in patients with type 2 diabetes (T2D). This study concluded that patients with T2D who had OH showed poorer cognitive function compared to patients who did not have OH.

This study investigated the safety and effectiveness of peficitinib (Smyraf) in patients with unresponsive rheumatoid arthritis (RA). 

They found that this treatment reduced RA symptoms and was well tolerated in these patients.

This study investigated the safety and effectiveness of upadacitinib (Rinvoq) in patients with rheumatoid arthritis (RA) who progressed after methotrexate (Otrexup). Researchers suggested that upadacitinib improved clinical and functional outcomes in these patients.